23 junio 2015
The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers concluded that the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/EWFShf9SFOY/150623072250.htm
